Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | HPGDS | O60760 | 3/20 | 0.50 |
| ▸ | F10 | P00742 | 5/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | CFD | P00746 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109569 | 0.91 | HDAC6 (0.57) | CTSBCTSSCTSKHPGDSHDAC1 | |
| SCHEMBL1109400 | 0.87 | CTSB (0.47) | CTSBCTSSCTSKHPGDS | |
| SCHEMBL1912269 | 0.86 | HDAC1 (0.50) | CTSBCTSSCTSKCTSLHPGDS | |
| SCHEMBL1109496 | 0.86 | AOC3 (0.60) | CTSBCTSSCTSKCTSLHPGDS | |
| SCHEMBL1109277 | 0.86 | HPGDS (0.65) | HPGDSHDAC1HDAC6 | |
| SCHEMBL1109563 | 0.86 | HPGDS (0.49) | CTSBCTSSCTSKCTSLHPGDS | |
| SCHEMBL401005 | 0.85 | HPGDS (0.54) | CTSBCTSSCTSKHPGDSHDAC1 | |
| SCHEMBL401441 | 0.85 | HPGDS (0.54) | CTSBCTSSCTSKHPGDSHDAC1 | |
| SCHEMBL1912117 | 0.85 | ANPEP (0.48) | CTSBCTSSCTSKCTSLHPGDS | |
| SCHEMBL1109523 | 0.85 | C3AR1 (0.55) | CTSSHPGDSHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | CTSB 259/4885CTSS 300/4885CTSK 430/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | CTSB 259/4885CTSS 300/4885CTSK 430/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | CTSB 259/4885CTSS 300/4885CTSK 430/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | CTSB 259/4885CTSS 300/4885CTSK 430/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | CTSB 259/4885CTSS 300/4885CTSK 430/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | CTSB 259/4885CTSS 300/4885CTSK 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.